Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
202
-
Total 13F shares, excl. options
-
53.7M
-
Shares change
-
-1.1M
-
Total reported value, excl. options
-
$2.24B
-
Value change
-
+$1.23M
-
Put/Call ratio
-
0.57
-
Number of buys
-
124
-
Number of sells
-
-103
-
Price
-
$41.58
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2020
282 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q2 2020.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 202 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.7M shares
of 62.7M outstanding shares and own 85.75% of the company stock.
Largest 10 shareholders include FMR LLC (7.79M shares), VANGUARD GROUP INC (4.73M shares), BlackRock Inc. (3.19M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.82M shares), D. E. Shaw & Co., Inc. (2.12M shares), STATE STREET CORP (2.12M shares), GREAT POINT PARTNERS LLC (2.1M shares), CITADEL ADVISORS LLC (1.76M shares), Invesco Ltd. (1.74M shares), and JANUS HENDERSON GROUP PLC (1.46M shares).
This table shows the top 202 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.